Eosinophils
Effector granulocytes
- Expression
- Massively infiltrated in tissue
- Evidence level
- established
- Targeted by
- Mepolizumab, Benralizumab
Role in pathogenesis
Tissue eosinophilia is the hallmark of CRSwNP. Eosinophils release MBP, ECP, EDN, and EPO — cytotoxic proteins that damage epithelium and perpetuate inflammation. Eosinophil counts in polyps correlate with recurrence.
Targeting drugs (2)
| Drug | Mechanism | Response | Line |
|---|---|---|---|
| Mepolizumab | Anti–IL-5 monoclonal antibody | Significant NPS reduction | 1st-line biologic |
| Benralizumab | Anti–IL-5Rα monoclonal antibody (ADCC-mediated eosinophil depletion) | Near-complete eosinophil depletion | 1st-line biologic |